THY1 and neoplasm: CD90, CD133 and CD44s expression was detected in less than 5% of tumor buds, while CD166, CD24 and ALDH1 were expressed in 34%, 16.2% and 16.5% of cases, respectively, in a study evaluating eight CSC biomarkers [79].